Moderna shares advanced after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed its full-year sales forecast. Covid vaccine sales totaled $1.8 ...

The primary outcome of the study was to demonstrate noninferior vaccine efficacy against COVID-19 starting 14 days after mNexspike compared with that after the comparator vaccine. Findings showed ...

Findings showed mNexspike showed a 9.3% (99.4% CI, -6.6, 22.8) higher relative vaccine efficacy compared with Moderna’s original COVID-19 vaccine.

The case centered on whether Alnylam’s patents, U.S. Patent Nos. 11,246,933 and 11,382,979 were infringed by Moderna’s use of SM-102-a cationic lipid in Moderna’s COVID-19 vaccine formulations.

The approval was supported by data from the phase 3 NextCOVE study (NCT05815498), which was designed to compare mNexspike to Moderna’s bivalent COVID-19 vaccine (original and omicron BA.4/BA.5).

The Food and Drug Administration has approved Moderna's mNEXSPIKE (mRNA-1283), a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at ...

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.

TUESDAY, June 3, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory ...

The Brief Moderna's new option is a lower-dose version that is a step toward next-generation coronavirus vaccines. It’s called mNexspike. Moderna’s new COVID-19 vaccine is recommended as ...